Pfizer Inc. (NYSE:PFE) sales still tumbling from the loss of patent protection on its blockbuster cholesterol-lowering drug Lipitor, saw its sales decline to $51.6 billion last year. Pfizer Inc. (NYSE:PFE) shares after opening at $30.05 moved to $30.13 on last trade day and at the end of the day closed at $29.87. Company price to sales ratio in past twelve months was calculated as 3.70 and price to cash ratio as 5.89. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -4.26%.
Abbott Laboratories logo Abbott Laboratories (NYSE:ABT) is scheduled to be releasing its Q114 earnings data on Wednesday, April 16th. Abbott Laboratories (NYSE:ABT) shares advanced 1.94% in last trading session and ended the day on $37.74. ABT return on equity ratio is recorded as 13.30% and its return on assets is 7.20%. Abbott Laboratories (NYSE:ABT) yearly performance is 6.55%.
Merck & Co Inc. (NYSE:MRK) said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks. Merck & Co., Inc. (NYSE:MRK) shares moved down -0.63% in last trading session and was closed at $55.57, while trading in range of $54.95 – $56.73. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 11.90%.
Ariad Pharmaceuticals (NASDAQ:ARIA) has received an average rating of “Hold” from the twenty-four analysts that are presently covering the stock, AR Network reports. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $7.29. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -3.04%. On last trading day company shares ended up $7.02. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -12.43%. Analysts mean target price for the company is $9.06.